Literature DB >> 23824214

Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.

Lex Wunderink1, Roeline M Nieboer, Durk Wiersma, Sjoerd Sytema, Fokko J Nienhuis.   

Abstract

IMPORTANCE: Short-term outcome studies of antipsychotic dose-reduction/discontinuation strategies in patients with remitted first-episode psychosis (FEP) showed higher relapse rates but no other disadvantages compared with maintenance treatment; however, long-term effects on recovery have not been studied before.
OBJECTIVE: To compare rates of recovery in patients with remitted FEP after 7 years of follow-up of a dose reduction/discontinuation (DR) vs maintenance treatment (MT) trial.
DESIGN: Seven-year follow-up of a 2-year open randomized clinical trial comparing MT and DR.
SETTING: One hundred twenty-eight patients participating in the original trial were recruited from 257 patients with FEP referred from October 2001 to December 2002 to 7 mental health care services in a 3.2 million-population catchment area. Of these, 111 patients refused to participate and 18 patients did not experience remission. PARTICIPANTS After 7 years, 103 patients (80.5%) of 128 patients who were included in the original trial were located and consented to follow-up assessment. INTERVENTION: After 6 months of remission, patients were randomly assigned to DR strategy or MT for 18 months. After the trial, treatment was at the discretion of the clinician. MAIN OUTCOMES AND MEASURES: Primary outcome was rate of recovery, defined as meeting the criteria of symptomatic and functional remission. Determinants of recovery were examined using logistic regression analysis; the treatment strategy (MT or DR) was controlled for baseline parameters.
RESULTS: The DR patients experienced twice the recovery rate of the MT patients (40.4% vs 17.6%). Logistic regression showed an odds ratio of 3.49 (P = .01). Better DR recovery rates were related to higher functional remission rates in the DR group but were not related to symptomatic remission rates. CONCLUSIONS AND RELEVANCE: Dose reduction/discontinuation of antipsychotics during the early stages of remitted FEP shows superior long-term recovery rates compared with the rates achieved with MT. To our knowledge, this is the first study showing long-term gains of an early-course DR strategy in patients with remitted FEP. Additional studies are necessary before these results are incorporated into general practice. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN16228411.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23824214     DOI: 10.1001/jamapsychiatry.2013.19

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  109 in total

1.  Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project.

Authors:  Roman Kotov; Laura Fochtmann; Kaiqiao Li; Marsha Tanenberg-Karant; Eduardo A Constantino; Joan Rubinstein; Greg Perlman; Eva Velthorst; Anne-Kathrin J Fett; Gabrielle Carlson; Evelyn J Bromet
Journal:  Am J Psychiatry       Date:  2017-08-04       Impact factor: 18.112

2.  [The German research network for mental disorders].

Authors:  M Bauer; T Banaschewski; A Heinz; I Kamp-Becker; A Meyer-Lindenberg; F Padberg; M A Rapp; R Rupprecht; F Schneider; T G Schulze; H-U Wittchen
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

3.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 4.  Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.

Authors:  M Alvarez-Jimenez; B O'Donoghue; A Thompson; J F Gleeson; S Bendall; C Gonzalez-Blanch; E Killackey; L Wunderink; P D McGorry
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

5.  Consumers' Suggestions for Improving the Mental Healthcare System: Options, Autonomy, and Respect.

Authors:  Morgan Shields; Sara Scully; Heidi Sulman; Christina Borba; Nhi-Ha Trinh; Sara Singer
Journal:  Community Ment Health J       Date:  2019-06-07

Review 6.  Inefficient neural system stabilization: a theory of spontaneous resolutions and recurrent relapses in psychosis

Authors:  Lena Palaniyappan
Journal:  J Psychiatry Neurosci       Date:  2019-11-01       Impact factor: 6.186

7.  Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period?

Authors:  Martin Harrow; Thomas H Jobe
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

8.  Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health.

Authors:  S M Cotton; K M Filia; A Ratheesh; K Pennell; S Goldstone; P D McGorry
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-01       Impact factor: 4.328

9.  McLean OnTrack: a transdiagnostic program for early intervention in first-episode psychosis.

Authors:  Ann K Shinn; Kirsten W Bolton; Rakesh Karmacharya; Kathryn E Lewandowski; Cagri Yuksel; Justin T Baker; Virginie-Anne Chouinard; Samira M Pingali; Hilary Bye; Katherine Cederbaum; Dost Öngür
Journal:  Early Interv Psychiatry       Date:  2015-11-29       Impact factor: 2.732

Review 10.  Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.

Authors:  Nancy Sohler; Ben G Adams; David M Barnes; Gregory H Cohen; Seth J Prins; Sharon Schwartz
Journal:  Am J Orthopsychiatry       Date:  2015-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.